Preoperative plasma D-Dimer level is correlated with peritoneal cancer index of patients with pseudomyxoma peritonei

BMC Surg. 2022 Oct 31;22(1):372. doi: 10.1186/s12893-022-01812-8.

Abstract

Purpose: Accurate assessment of preoperative tumor burden contribute to formulate a scientific surgical plan for patients with pseudomyxoma peritonei (PMP). Present study aimed to assess whether the preoperative plasma D-Dimer level could reflect tumor burden for PMP patients.

Methods: A total of 253 PMP patients were included between June 1, 2013 and March 1, 2022. According to the peritoneal cancer index (PCI), all participants were divided into extensive (PCI ≥ 28) and none-extensive (PCI < 28) subgroups. The D-Dimer and tumor markers were compared between the two subgroups. The correlation between the abovementioned biomarkers and PCI will be calculated, and further compared with each other. Two-sided P value less than 0.05 is considered statistically significant.

Results: The level of D-Dimer (ng/ml) between extensive and none-extensive subgroup were 600 (328, 1268) vs. 339 (128, 598), Z = -5.425, p < 0.001. The Spearman correlation between D-Dimer, carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA 125), CA 19 - 9 and PCI were 0.487, 0.509, 0.469, and 0.499, respectively (all p < 0.001). The correlation coefficients were compared with each other according to Meng, Rosenthal and Rubin's method, however, there was no significant difference.

Conclusion: Preoperative plasma D-Dimer could moderately reflect tumor burden for PMP. In the future, a multivariate prediction model will be developed to help surgeons to formulate a more precise surgical plan for the PMP patients.

Keywords: Burden; Pseudomyxoma peritonei; Tumor marker.

MeSH terms

  • CA-19-9 Antigen
  • Fibrin Fibrinogen Degradation Products
  • Humans
  • Hyperthermia, Induced*
  • Peritoneal Neoplasms* / diagnosis
  • Peritoneal Neoplasms* / surgery
  • Pseudomyxoma Peritonei* / diagnosis
  • Pseudomyxoma Peritonei* / surgery
  • Retrospective Studies

Substances

  • fibrin fragment D
  • Fibrin Fibrinogen Degradation Products
  • CA-19-9 Antigen

Grants and funding